Gene Solutions Receives FDA Breakthrough Device Designation for SPOT-MAS 10 Multi-Cancer Blood Test
核心洞察
Gene Solutions (搜索) announced FDA Breakthrough Device Designation for SPOT-MAS 10 (搜索), a multi-omic blood test designed to detect cancer-associated signals across 10 cancer types in asymptomatic adults aged 40 and older.
The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using machine learning to identify cancers including breast, lung, liver, colorectal, gastric, ovarian, pancreatic, esophageal, endometrial and head & neck cancers.
SPOT-MAS demonstrated strong performance in the K-DETEK study with over 9,000 participants and has been used in more than 100,000 individuals in real-world practice across Asia.
Gene Solutions (搜索), a Singapore-based biotechnology company, has received FDA Breakthrough Device Designation for SPOT-MAS 10 (搜索), a multi-omic blood test designed to detect cancer-associated signals across 10 common and aggressive cancer types. The designation marks a significant regulatory milestone for the company's multi-cancer early detection technology as it prepares for a planned U.S. market entry in late 2026.
Multi-Omic Approach to Cancer Detection
SPOT-MAS 10 (搜索) is described as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect cancer-associated signals in asymptomatic adults aged 40 years and older.
The assay targets 10 cancer types divided into two distinct categories: five common cancers with established screening pathways (breast, lung, liver, colorectal, and gastric) and five aggressive, less common cancers that currently lack standard screening methods (ovarian, pancreatic, esophageal, endometrial, and head & neck cancers).
"Early cancer detection requires more than identifying a single molecular signal. By integrating multiple layers of cell-free DNA information with machine learning, SPOT-MAS is designed to extract deeper biological signals from blood while maintaining the high specificity required for responsible screening," said Dr. Le Son Tran, Principal Investigator of SPOT-MAS.
Clinical Validation and Real-World Evidence
SPOT-MAS has undergone extensive clinical validation through the K-DETEK prospective cohort study, which enrolled more than 9,000 asymptomatic participants. Results from this study, published in BMC Medicine, demonstrated high specificity and the ability to identify cancer-associated signals across multiple cancer types. In March 2025, SPOT-MAS became the first multi-cancer early detection blood test in Asia to complete a large prospective cohort validation.
Beyond controlled study settings, Gene Solutions (搜索) reports that SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed across diverse clinical environments. Real-world data were presented at ESMO Asia 2025 and are scheduled for presentation at ASCO Breakthrough 2026 in Singapore.
Regulatory Pathway and Market Strategy
The FDA's Breakthrough Device Designation is intended to expedite development and review of devices that may provide more effective diagnosis of life-threatening or irreversibly debilitating conditions. While the designation provides prioritized engagement with the FDA, it does not constitute approval, clearance, or marketing authorization, and the device remains subject to applicable regulatory review requirements.
"Receiving FDA Breakthrough Device Designation for SPOT-MAS 10 (搜索) is a defining milestone for Gene Solutions (搜索) and reflects the potential of our multi-omic approach in cancer screening," said Dr. Nguyen Hoai Nghia, CEO & Co-founder of Gene Solutions. "This recognition strengthens our commitment to advancing accessible, evidence-based technologies that support earlier detection of cancers, especially for those where screening options remain limited — ultimately helping to improve patient outcomes worldwide."
Current Availability and Future Plans
SPOT-MAS is currently available through select hospitals and clinics across Asia, with additional availability in Brazil, Turkey, and the Middle East. The company emphasizes that SPOT-MAS 10 (搜索) is designed to complement, not replace, existing guideline-recommended screening programs, with positive results intended to be followed by physician-directed diagnostic evaluation based on the predicted tissue of origin.
The SPOT-MAS platform is built on a multi-omic approach integrating genetics, epigenetics, and fragmentomics, combined with AI-driven analysis, prospective validation, and real-world evidence. Gene Solutions (搜索) is targeting U.S. launch readiness in late 2026, supported by ongoing U.S. laboratory and validation activities.